AUTL Share Price Performance
US$1.66
-2.45 (-59.61%)
82.7% undervalued intrinsic discount
US$9.62
Fair Value
Price US$1.66
AnalystConsensusTarget US$9.62
Fair ValueUS$9.62
Share PriceUS$1.66
82.7% undervalued intrinsic discount
Autolus Therapeutics plc Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 18 Fair Values set on narratives written by author
AUTL Community Narratives
AN
Fair Value US$9.62 81.7% undervalued intrinsic discount
Robust Clinical Uptake Will Expand Advanced Cancer Therapy Adoption
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
Recent AUTL News & Updates
Autolus Therapeutics plc Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.86
- Gross Margin
- -516.17%
- Net Profit Margin
- -760.94%
- Debt/Equity Ratio
- 70.6%
Autolus Therapeutics plc Competitors
Snowflake Analysis
About AUTL
- Founded
- 2014
- Employees
- 649
- CEO
- WebsiteView website
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company’s clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
U.K. Market Performance
- 7 Days: 0.8%
- 3 Months: 6.3%
- 1 Year: 14.3%
- Year to Date: 14.6%
Over the last 7 days, the market has remained flat, although notably the Materials sector gained 3.5% in that time. More promisingly, the market is up 14% over the past year. Looking forward, earnings are forecast to grow by 14% annually. Market details ›